35 assets in Secondary Progressive Multiple Sclerosis

Therapeutic assets addressing Secondary Progressive Multiple Sclerosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Siponimod Secondary Progressive Multiple Sclerosis	Novartis Pharmaceuticals	P4	BBB (75)
Rituximab Secondary Progressive Multiple Sclerosis	Cairo University	P3	BB (70)
Ocrelizumab Secondary Progressive Multiple Sclerosis	Indapta Therapeutics, INC.	P3	BB (64)
Remibrutinib Secondary Progressive Multiple Sclerosis	Moein Amin	P3	BB (64)
Tolebrutinib Secondary Progressive Multiple Sclerosis	Sanofi	P3	BB (64)
Fexofenadine Secondary Progressive Multiple Sclerosis	Rigshospitalet, Denmark	P3	B (60)
Kyv-101 Secondary Progressive Multiple Sclerosis	Kyverna Therapeutics	P2	B (60)
Metformin Secondary Progressive Multiple Sclerosis	University Hospital, Antwerp	P2	B (60)
Orelabrutinib Secondary Progressive Multiple Sclerosis	Zenas BioPharma (USA), LLC	P3	B (60)
Teriflunomide Secondary Progressive Multiple Sclerosis	Sanofi	P3	B (60)
Cladribine Secondary Progressive Multiple Sclerosis	University Hospital, Strasbourg, France	P2/3	B (57)
Physiologic Sodium Chloride Solution Secondary Progressive Multiple Sclerosis	Institute of Psychiatry and Neurology, Warsaw	P2/3	B (56)
Mayzent Secondary Progressive Multiple Sclerosis	State University of New York at Buffalo	P2/3	CCC (55)
Acetylcysteine Secondary Progressive Multiple Sclerosis	Emmanuelle Waubant, MD PhD	P2	CCC (53)
Foralumab Secondary Progressive Multiple Sclerosis	Tiziana Life Sciences LTD	P2	CCC (53)
Foralumab Tzls-401 Secondary Progressive Multiple Sclerosis	Tiziana Life Sciences LTD	P2	CCC (53)
Hydroxychloroquine Secondary Progressive Multiple Sclerosis	University of Calgary	P2	CCC (53)
Indapamide Secondary Progressive Multiple Sclerosis	University of Calgary	P2	CCC (53)
Bendamustine Secondary Progressive Multiple Sclerosis	Tr1X, Inc.	P1/2	CCC (48)
trx319 Secondary Progressive Multiple Sclerosis	Tr1X, Inc.	P1/2	CCC (48)
Scm-010 Secondary Progressive Multiple Sclerosis	Stem Cell Medicine Ltd.	P1/2	CC (47)
Pipe-791 Secondary Progressive Multiple Sclerosis	Contineum Therapeutics	P1	CC (46)
Cyclophosphamide Secondary Progressive Multiple Sclerosis	Indapta Therapeutics, INC.	P1	CC (43)
Dasatinib Secondary Progressive Multiple Sclerosis	Ohio State University	P1	CC (43)
Ferumoxytol Secondary Progressive Multiple Sclerosis	University of Utah	Early P1	CC (43)
Flavone, 3,3',4',5,7-Pentahydroxy- Secondary Progressive Multiple Sclerosis	Ohio State University	P1	CC (43)
Fludarabine Secondary Progressive Multiple Sclerosis	Indapta Therapeutics, INC.	P1	CC (43)
Gadoteridol Secondary Progressive Multiple Sclerosis	University of Utah	Early P1	CC (43)
hbi0101 cart Secondary Progressive Multiple Sclerosis	Polina Stepensky	P1	CC (43)
Idp-023 Secondary Progressive Multiple Sclerosis	Indapta Therapeutics, INC.	P1	CC (43)
Intranasal Foralumab Secondary Progressive Multiple Sclerosis	Tiziana Life Sciences LTD	P1	CC (43)
Mesna Secondary Progressive Multiple Sclerosis	Indapta Therapeutics, INC.	P1	CC (43)
Orca-Q Secondary Progressive Multiple Sclerosis	Stanford University	P1	CC (43)
s103 cells Secondary Progressive Multiple Sclerosis	Xijing Hospital	P1	CC (43)
ng01 - autologous bone marrow derived human stromal cells Secondary Progressive Multiple Sclerosis	NeuroGenesis Ltd.	P2	NR ()